A new strategy for treating patients with CD7+, CD4-, CD8- acute lymphoblastic leukaemia.
Ono
K
K
Yoshida
T
T
Tsuchiya
K
K
Nakazato
S
S
Nagumo
F
F
Shimamoto
Y
Y
D000368:Aged; D015703:Antigens, CD / Q000032:analysis*; D019011:Antigens, CD7 / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D015704:CD4 Antigens / Q000032:analysis*; D016827:CD8 Antigens / Q000032:analysis*; D004317:Doxorubicin / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage
D015703:Antigens, CD; D019011:Antigens, CD7; D015704:CD4 Antigens; D016827:CD8 Antigens; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D014750:Vincristine; D004317:Doxorubicin; D011239:Prednisolone